CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...